PharmaPoint: Psoriatic Arthritis – Global Drug Forecast and Market Analysis to 2025

Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially those of the lower extremities and distal joints of the fingers and toes as well as the back and sacroiliac joints of the pelvis. In approximately 80% of PsA patients, skin lesions of psoriasis (PsO), an immune-mediated skin disease, manifest prior to the development of PsA, typically by five to 10 years. PsA most commonly develops between the ages of 30 and 50 and affects men and women equally. Although, early diagnosis and intervention are key in preventing irreversible joint damage, many PsA patients are undiagnosed and go untreated for months or years.

GlobalData projects the PsA market in 7MM to experience strong growth during the forecast period at a CAGR of 10.74%. By the forecast's end in 2025, sales will increase to over $12.58 billion from $4.53 billion in 2015. This growth will be driven primarily by the increase in diagnosed prevalent cases from 1,044,022 in 2015 to 1,520,471 in 2025. Further, the launch of the IL-17 inhibitors, including Novartis' Cosentyx, Eli Lilly's Taltz, and AstraZeneca's Lumicef, as well as the launch of Celgene's oral therapy Otezla, will expand the treatment armamentarium for PsA driving growth in the market.

Scope

Overview of PsA, including epidemiology, etiology, pathophysiology, symptoms and country-specific diagnosis and treatment recommendations.

Annualized PsA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the PsA market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of novel products- including promising IL-17 inhibitors – and biosimilars – such as Celltrion’s Hospira, Sandoz’s Erelzi, Biogen/Samsung Bioepies’ Flixabi and Benepali, and Amgen’s Amjevita.

Analysis of the current and future market competition in the global PsA market (7MM). Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

How large an impact will biosimilars have on the PsA market? What do dermatologists, rheumatologists, and key opinion leaders across the 7MM think about the evolving treatment landscape?

What opportunities remain in the market for new product entrants?

What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the PsA market?

According to KOLs, what are the most important unmet needs in PsA? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2025?

What clinical and commercial factors are likely to affect uptake of PsA therapies in the US, 5EU, and Japan?

Companies mentioned

Amgen

AbbVie

Celgene

Eli Lilly

Johnson & Johnson

UCB

Bristol-Myers Squibb

Novartis

Pfizer

AstraZeneca

Alder

Amgen

AbbVie

Celgene

Eli Lilly

Johnson & Johnson

UCB

Bristol-Myers Squibb

Novartis

Pfizer

AstraZeneca

Alder

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology ...

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.2Symptoms

3.3Quality of Life

4Epidemiology

4.1Disease Background

4.2Risk Factors and Comorbidities

4.3Global Trends

4.4Forecast Methodology

4.4.1Sources Used

4.4.2Forecast Assumptions and Methods

4.4.3Sources Not Used

4.5Epidemiological Forecast for PsA (2015–2025)

4.5.1Diagnosed Prevalent Cases of PsA

4.5.2Age-Specific Diagnosed Prevalent Cases of PsA

4.5.3Sex-Specific Diagnosed Prevalent Cases of PsA

4.5.4Age-Standardized Diagnosed Prevalence of PsA

4.5.5Diagnosed Prevalent Cases by Type

4.5.6Diagnosed Prevalent Cases by Joint Involvement

4.6Alternative Forecast of Diagnosed Prevalent Cases of PsA

4.7Discussion

4.7.1Epidemiological Forecast Insight

4.7.2Limitations of the Analysis

4.7.3Strengths of the Analysis

5Disease Management

5.1Diagnosis and Treatment Overview

5.1.1Diagnosis

5.1.2Disease Activity

5.1.3Treatment Guidelines and Leading Prescribed Drugs

5.1.4Clinical Practice

5.2US

5.35EU

5.4Japan

6Competitive Assessment

6.1Overview

6.2Product Profiles – Major Brands

6.2.1Enbrel (etanercept)

6.2.2Humira (adalimumab)

6.2.3Simponi (golimumab)

6.2.4Remicade (infliximab)

6.2.5Cimzia (certolizumab pegol)

6.2.6Cosentyx (secukizumab)

6.2.7Lumicef (brodalumab)

6.2.8Taltz (ixekizumab)

6.2.9Stelara (ustekinumab)

6.2.10Otezla (apremilast)

6.3Other Therapeutic Classes

7Unmet Needs and Opportunities

7.1Overview

7.2Increased Awareness Among Dermatologists and Primary Care Physicians

7.2.1Unmet Need

7.2.2Gap Analysis

7.2.3Opportunity

7.3Early Diagnosis and Treatment

7.3.1Unmet Need

7.3.2Gap Analysis

7.3.3Opportunity

7.4Improved Drug Safety and Efficacy Profiles

7.4.1Unmet Need

7.4.2Gap Analysis

7.4.3Opportunity

7.5Development of Cost-Effective Therapies

7.5.1Unmet Need

7.5.2Gap Analysis

7.5.3Opportunity

8Pipeline Assessment

8.1Overview

8.2Clinical Trial Mapping

8.2.1Clinical Trials by Class

8.3Promising Drugs in Clinical Development

8.3.1Xeljanz (tofacitinib)

8.3.2Orencia (abatacept)

8.3.3Clazakizumab

8.4Other Drugs in Development

8.5Biosimilars

8.5.1Introduction

8.5.2Biosimilars Versus Branded Biologics in Key Autoimmune Diseases

8.5.3Biosimilars in the Immunology Community

8.5.4By the Numbers: Biosimilars in Development

8.5.5The Impact of Biosimilars Will Be Felt Throughout the Pharmaceutical Industry

8.5.6Uptake of Biosimilars is Expected to Vary by Market

9Current and Future Players

9.1Overview

9.2Trends in Corporate Strategy

9.3Company Profiles

9.3.1Amgen

9.3.2AbbVie

9.3.3Johnson & Johnson

9.3.4UCB

9.3.5Novartis

9.3.6Celgene

9.3.7Pfizer

9.3.8Bristol-Myers Squibb

9.3.9AstraZeneca

9.3.10Eli Lilly

9.3.11Alder

10Market Outlook

10.1Global Markets

10.1.1Forecast

10.1.2Drivers and Barriers – Global Issues

10.2US

10.2.1Forecast

10.2.2Key Events

10.2.3Drivers and Barriers

10.35EU

10.3.1Forecast

10.3.2Key Events

10.3.3Drivers and Barriers

10.4Japan

10.4.1Forecast

10.4.2Key Events

10.4.3Drivers and Barriers

11Appendix

11.1Bibliography

11.2Abbreviations

11.3Methodology

11.4Forecasting Methodology

11.4.1Diagnosed Psoriatic Arthritis Patients

11.4.2Percent Drug-Treated Patients

11.4.3Drugs Included in Each Therapeutic Class

11.4.4Launch and Patent Expiry Dates

11.4.5General Pricing Assumptions

11.4.6Individual Drug Assumptions

11.4.7Generic Erosion

11.4.8Pricing of Pipeline Agents

11.5Primary Research – Key Opinion Leaders Interviewed for This Report

11.6Primary Research – Prescriber Survey

11.7About the Authors

11.7.1Analyst

11.7.2Therapy Area Director

11.7.3Epidemiologist

11.7.4Global Director of Therapy Analysis and Epidemiology

11.8About GlobalData

11.9Contact Us

11.10Disclaimer

List of Tables

Table 1: Symptoms of PsA

Table 2: Risk Factors for and Comorbidities of PsA

Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases ...

Table 1: Symptoms of PsA

Table 2: Risk Factors for and Comorbidities of PsA

Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PsA

Table 4: Sources Used to Forecast Proportion of Diagnosed Prevalent Cases of PsA by Type

Table 5: 7MM, Diagnosed Prevalent Cases of PsA, Ages =18 Years, Both Sexes, N, Selected Years 2015–2025

Table 6: 7MM, Age-Specific, Diagnosed Prevalent Cases of PsA, Both Sexes, N (Row %), 2015

Table 7: 7MM, Sex-Specific Diagnosed Prevalent Cases of PsA, Ages =18, N (Row %), 2015

Table 8: 7MM, Alternative Diagnosed Prevalent Cases of PsA, Ages =18 Years, Both Sexes, N, Selected Years 2015–2025

Table 9: CASPAR Diagnostic Criteria for PsA

Table 10: Treatment Guidelines for PsA

Table 11: Overarching Principles of PsA GRAPPA Treatment Recommendations, 2015

Table 12: GRAPPA Treatment Guidelines for PsA, 2015

Table 13: Updated EULAR Overarching Principles for PsA, 2015

Table 14: Updated EULAR Recommendations for the Management of PsA, 2015

Table 15: Country Profile – US

Table 16: Country Profile – 5EU

Table 17: Country Profile – Japan

Table 18: Leading Branded Treatments for PsA, 2015

Table 19: Product Profile – Enbrel

Table 20: Enbrel SWOT Analysis, 2015

Table 21: Product Profile – Humira

Table 22: Humira SWOT Analysis, 2015

Table 23: Product Profile – Simponi

Table 24: Simponi SWOT Analysis, 2015

Table 25: Product Profile – Remicade

Table 26: Remicade SWOT Analysis, 2015

Table 27: Product Profile – Cimzia

Table 28: Cimzia SWOT Analysis, 2015

Table 29: Product Profile – Cosentyx

Table 30: Cosentyx SWOT Analysis, 2015

Table 31: Product Profile – Lumicef

Table 32: Lumicef SWOT Analysis, 2015

Table 33: Product Profile – Taltz

Table 34: Taltz SWOT Analysis, 2015

Table 35: Product Profile – Stelara

Table 36: Stelara SWOT Analysis, 2015

Table 37: Product Profile – Otezla

Table 38: Otezla SWOT Analysis, 2015

Table 39: Summary of Minor Therapeutic Classes for PsA, 2016

Table 40: Unmet Needs and Opportunities in PsA

Table 41: Comparison of Therapeutic Classes in Development for PsA, 2016

Table 42: Product Profile – Xeljanz

Table 43: Clinical Trials Demonstrating Xeljanz as a Potential Treatment for PsA

Table 44: Xeljanz SWOT Analysis, 2015

Table 45: Product Profile – Orencia

Table 46: Orencia SWOT Analysis, 2015

Table 47: Product Profile – Clazakizumab

Table 48: Clazakizumab SWOT Analysis, 2015

Table 49: Drugs in Development for PsA, 2016

Table 50: Clinical Trials Demonstrating the Efficacy of Biosimilars to Branded Biologics

Table 51: 7MM, Marketed and Pipeline Biosimilars for PsA, 2016

Table 52: 7MM, Physician Uptake of Biosimilar Products for PsA, 2016

Table 53: 7MM, Key Companies in the PsA Market, 2015

Table 54: Amgen’s PsA Portfolio Assessment, 2015

Table 55: AbbVie’s PsA Portfolio Assessment, 2015

Table 56: J&J’s PsA Portfolio Assessment, 2015

Table 57: UCB’s PsA Portfolio Assessment, 2015

Table 58: Novartis’ PsA Portfolio Assessment, 2015

Table 59: Celgene’s PsA Portfolio Assessment, 2015

Table 60: Pfizer’s PsA Portfolio Assessment, 2015

Table 61: BMS’ PsA Portfolio Assessment, 2015

Table 62: AstraZeneca’s PsA Portfolio Assessment, 2015

Table 63: Eli Lilly’s PsA Portfolio Assessment, 2015

Table 64: Alder’s PsA Portfolio Assessment, 2015

Table 65: PsA Market – Global Drivers and Barriers, 2015?2025

Table 66: Key Events Impacting Sales for PsA in the US, 2015–2015

Table 67: PsA Market – US Drivers and Barriers, 2015?2025

Table 68: Key Events Impacting Sales for PsA in the 5EU, 2015–2015

Table 69: PsA Market – 5EU Drivers and Barriers, 2015?2025

Table 70: Key Events Impacting Sales for PsA in Japan, 2015–2015

Table 71: PsA Market – Japan Drivers and Barriers, 2015?2025

Table 72: 7MM, Key Launch Dates

Table 73: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of PsA, Ages =18 Years, Both Sexes, N, 2015–2025

Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of PsA ...

Figure 1: 7MM, Diagnosed Prevalent Cases of PsA, Ages =18 Years, Both Sexes, N, 2015–2025

Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of PsA, Both Sexes, N, 2015

Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of PsA, Ages =18, 2015

Figure 4: 7MM, Age-Standardized Diagnosed Prevalence Rate of PsA, Ages =18, N, 2015

Figure 5: 7MM, Diagnosed Prevalent Cases of PsA by Type, Both Sexes, Ages =18, 2015

Figure 6: 7MM, Diagnosed Prevalent Cases of PsA by Joint Involvement, Both Sexes, Ages =18, 2015

Figure 7: 7MM, Alternative Diagnosed Prevalent Cases of PsA, Ages =18 Years, Both Sexes, N, Selected Years 2015–2025

Figure 8: Original GRAPPA Treatment Guidelines for PsA, 2009

Figure 9: EULAR 2015 Recommendations for the Management of PsA, Phase I

Figure 10: EULAR 2015 Recommendations for the Management of PsA, Phase II

Figure 11: EULAR 2015 Recommendations for the Management of PsA, Phase III

Figure 12: EULAR 2015 Recommendations for the Management of PsA, Phase IV

Figure 13: PsA Clinical Trials by Drug Class, 2016

Figure 14: PsA – Phase IIb–III Pipeline, 2016

Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in PsA, 2015–2025

Figure 16: Clinical and Commercial Positioning of Xeljanz

Figure 17: Clinical and Commercial Positioning of Orencia

Figure 18: Clinical and Commercial Positioning of Clazakizumab

Figure 19: Biosimilar Prescribing Habits in PsA Across the 7MM, 2016

Figure 20: Global Sales of Branded Products for PsA by Company, 2015–2025

Figure 21: Company Portfolio Gap Analysis in PsA, 2015–2025

Figure 22: Global Sales for PsA by Region, 2015–2025

Figure 23: US Sales for PsA by Drug Class, 2015–2025

Figure 24: 5EU Sales for PsA by Drug Class, 2015–2025

Figure 25: Japan Sales for PsA by Drug Class, 2015–2025

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports